The US Food and Drug Administration signaled its interest in helping to bring continuous glucose monitoring to hospital inpatients by granting its breakthrough device designation to DexCom’s continuous glucose monitoring system.
Early in the pandemic in April 2020, the agency used its enforcement discretion to let Dexcom and Abbott to put...